Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday. They currently have a $11.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 103.70% from the company’s previous close.
A number of other research analysts have also recently commented on the company. Oppenheimer cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Evercore ISI reiterated an “outperform” rating and issued a $9.00 price objective (down from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Piper Jaffray Companies cut Axovant Sciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $32.00 to $9.00 in a report on Tuesday, September 26th. Finally, UBS cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $14.13.
Axovant Sciences (NASDAQ AXON) opened at $5.40 on Friday. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/12/03/hc-wainwright-reiterates-buy-rating-for-axovant-sciences-axon.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
What are top analysts saying about Axovant Sciences Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axovant Sciences Ltd. and related companies.